Crystalline polymorphs of benfotiamine, process for preparation and its use thereof

    公开(公告)号:US09718846B1

    公开(公告)日:2017-08-01

    申请号:US14432079

    申请日:2012-10-31

    摘要: The present invention is directed to crystalline polymorphs of benfotiamine, its methods of preparation and its use thereof. Five crystalline polymorphs of benfotiamine are designated as crystalline forms A, B, C, D and E, and may be distinguished by their respective patterns of X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), infrared spectroscopy (IR), raman spectroscopy, moreover by their diverse preparing process. The crystalline polymorphs of the present invention are useful as they act in treating Vitamin B1 deficiency, metabolic disorders, mental illness and disorders, diabetes complications, neurodegerative diseases. Further the present invention is a process for preparing and transforming diverse crystalline form of benfotiamine through different synthesis routes and varied solvents and combinations. The crystalline polymorphs of the present invention are basically pure. The present invention not only provides new crystalline forms of benfotiamine, but also provides its new solvates, especially hydrates.

    Heterocycle-substituted diphosphonate compounds, pharmaceutical
compositions, and methods of treating abnormal calcium and phosphate
metabolism
    4.
    发明授权
    Heterocycle-substituted diphosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism 失效
    杂环取代的二膦酸盐化合物,药物组合物和治疗异常钙和磷酸盐代谢的方法

    公开(公告)号:US5334586A

    公开(公告)日:1994-08-02

    申请号:US779705

    申请日:1991-10-21

    摘要: The present invention relates to novel heterocycle-substituted diphosphonic acids, and the pharmaceutically-acceptable salts and esters thereof, in which the diphosphonate-substituted carbon atom moiety is attached to a carbon atom in a nitrogen-containing six membered ring heterocycle, preferably a piperidine ring. The heterocycle-substituted diphosphonic acid compounds have the general structure: ##STR1## wherein Z is a nitrogen-containing six membered ring heterocycle moiety selected from piperidinyl, diazinyl and triazinyl; m, n and m+n are from 0 to 10; Q is a covalent bond or a moiety selected from oxygen, sulfur or nitrogen; and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are substituent groups.The present invention further relates to pharmaceutical compositions containing these novel compounds. Finally this invention relates to methods for treating or preventing diseases characterized by abnormal calcium and phosphate metabolism by utilizing a compound or pharmaceutical composition of the present invention.

    摘要翻译: 本发明涉及新颖的杂环取代二膦酸及其药学上可接受的盐和酯,其中二膦酸酯取代的碳原子部分连接到含氮六元环杂环中的碳原子上,优选哌啶 环。 杂环取代的二膦酸化合物具有以下一般结构:其中Z是选自哌啶基,二嗪基和三嗪基的含氮六元环杂环部分。 m,n和m + n为0〜10; Q是共价键或选自氧,硫或氮的部分; 并且R1,R2,R3和R4是取代基。 本发明还涉及含有这些新化合物的药物组合物。 最后本发明涉及利用本发明的化合物或药物组合物治疗或预防以异常钙和磷酸盐代谢为特征的疾病的方法。